New drug trial aims to cure advanced breast cancer with few metastases
NCT ID NCT05982678
Summary
This trial is testing whether the drug trastuzumab-deruxtecan (T-DXd) can cure HER2-positive breast cancer that has spread to only 1-3 distant sites in the body. It will enroll 72 patients who have not received prior treatment for this spread. The goal is to use the drug before and after local treatments (like radiation or surgery) to achieve deep, lasting remission and potentially eliminate the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Antoni van Leeuwenhoek
RECRUITINGAmsterdam, Netherlands
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.